MedPath

Transplantation of autologous mononuclear cells in patients with critical limb ischemia (CLI)

Phase 2
Conditions
CLI (atherosclerotic PAD/Buerger disease)
Registration Number
JPRN-UMIN000005232
Lead Sponsor
Regenerative Medicine Unit, Division of Vascular Regeneration Therapy, Institute of Biomedical Research and Innovation (IBRI)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
5
Inclusion Criteria

Not provided

Exclusion Criteria

1) CLI within category 6 on the Rutherford's scale 2) Less than 3 months since success of bypass surgery, transluminal angioplasty and sympathectomy for the limb expected to be transplanted 3) Left ventricular ejection fraction< 25% 4) Patients with a history of severe side effects to apheresis 5) Patients with malignant tumor 6) Patients with diabetic proliferating retinopathy (new Fukuda classification Bii to BV) 7) Less than 3 months since last episode of unstable angina and myocardial/cerebral infarction 8) Patients with cirrhosis of the liver 9) Leukocytes exceeding 15,000/ micro L 10) Platelets less than 100,000/ micro L 11) Hemoglobin less than 8 g/dL 12) Patients with rest pain, ulcer or necrosis for reasons other than CLI (such as lumber spinal canal stenosis, arthropathy or vasculitis) 13) Patients who require major amputation regardless of whether revascularization is successful or not, because of exposure of the bone or tendon due to osteomyelitis, osteonecrosis, ulcer and soft tissue necrosis, or sepsis 14) Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period 15) Patients enrolled in any other clinical trial 16) Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
We will exploratorily evaluate the following concerns without configuring primary outcomes. 1) Fontaine&#39;s grade and Rutherford&#39;s category 2) All-cause mortality and cause of death 3) Major amputation and unplanned minor amputation 4) Size of ulcer 5) Severity of ischemic leg pain 6) Physiological findings of lower extremity ischemia
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath